Vera Therapeutics (VERA) is back in focus after third quarter results showed a net loss of US$93.71 million, as the company leans into the TRUTAKNA launch and files for full FDA approval. Against this...
Source LinkVera Therapeutics (VERA) is back in focus after third quarter results showed a net loss of US$93.71 million, as the company leans into the TRUTAKNA launch and files for full FDA approval. Against this...
Source Link
Comments